← Back to Screener
Avalo Therapeutics, Inc. Common Stock (AVTX)
Price$15.75
Value ScoreF
Growth ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-26.02%
Price vs S&P 500 (4W)11.37%
VGM Score22.23
Market Capitalization$838.42M
All Metrics
Book Value / Share (Quarterly)$2.77
P/TBV (Annual)8.32x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-85.16%
Cash Flow / Share (Quarterly)$-2.42
Price vs S&P 500 (YTD)-23.10%
Gross Margin (TTM)242.18%
Net Profit Margin (TTM)-23254.24%
EPS (TTM)$-6.04
10-Day Avg Trading Volume1.49M
EPS Excl Extra (TTM)$-6.04
Revenue Growth (5Y)-61.19%
EPS (Annual)$-5.84
ROI (Annual)-91.66%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-28808.20%
Cash / Share (Quarterly)$3.33
Revenue Growth QoQ (YoY)-69.27%
ROA (Last FY)-67.20%
Revenue Growth TTM (YoY)-86.62%
EBITD / Share (TTM)$-5.39
ROE (5Y Avg)-235.33%
Operating Margin (TTM)-33461.02%
Cash Flow / Share (Annual)$-2.78
P/B Ratio12.27x
P/B Ratio (Quarterly)5.35x
Net Income / Employee (Annual)$-2,371,500
EV / Revenue (TTM)13826.44x
Net Interest Coverage (TTM)-14.11x
ROA (TTM)-61.67%
EPS Incl Extra (Annual)$-5.84
Current Ratio (Annual)8.14x
Quick Ratio (Quarterly)7.08x
3-Month Avg Trading Volume1.17M
52-Week Price Return328.76%
Revenue / Employee (TTM)$1,800
Tangible BV / Share (Quarterly)$0.67
P/S Ratio (Annual)14210.52x
Asset Turnover (Annual)0.00x
52-Week High$24.27
Operating Margin (5Y Avg)-28457.44%
EPS Excl Extra (Annual)$-5.84
26-Week Price Return-10.09%
Quick Ratio (Annual)7.60x
13-Week Price Return-9.58%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)7.66x
Enterprise Value$815.76M
Revenue / Share Growth (5Y)-67.45%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$1,800
Inventory Turnover (Annual)128.40x
Pretax Margin (Annual)-132362.71%
Cash / Share (Annual)$5.31
3-Month Return Std Dev102.50%
Gross Margin (5Y Avg)93.93%
Net Income / Employee (TTM)$-2,367,000
ROE (Last FY)-94.23%
Net Interest Coverage (Annual)-3.00x
EPS Basic Excl Extra (Annual)$-5.84
Receivables Turnover (TTM)58.52x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-6.04
Receivables Turnover (Annual)34.06x
ROI (TTM)-76.00%
P/S Ratio (TTM)14210.52x
Pretax Margin (5Y Avg)-28747.55%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.45
Price vs S&P 500 (52W)300.56%
Year-to-Date Return-12.17%
5-Day Price Return-2.45%
EPS Normalized (Annual)$-5.84
ROA (5Y Avg)-94.16%
Net Profit Margin (Annual)-132642.37%
Month-to-Date Return19.03%
Cash Flow / Share (TTM)$-1.61
EBITD / Share (Annual)$-5.41
Operating Margin (Annual)-123601.69%
LT Debt / Equity (Annual)0.02x
ROI (5Y Avg)-173.22%
LT Debt / Equity (Quarterly)0.03x
EPS Basic Excl Extra (TTM)$-6.04
P/TBV (Quarterly)12.89x
P/B Ratio (Annual)3.97x
Inventory Turnover (TTM)128.90x
Pretax Margin (TTM)-23033.90%
Book Value / Share (Annual)$4.49
Price vs S&P 500 (13W)-19.33%
Beta0.78x
P/FCF (Annual)66.75x
Revenue / Share (TTM)$0.00
ROE (TTM)-77.76%
52-Week Low$3.58
vGradeF
gGradeF
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.98est. -1.05
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.31
4.35
4.35
4.33
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AVTXAvalo Therapeutics, Inc. Common Stock | F | F | C | $15.75 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Avalo Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies and fusion proteins to treat immune dysregulation disorders. The company's lead asset, AVTX-009, is an anti-IL-1B monoclonal antibody targeting inflammatory diseases. Additional pipeline candidates include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).